CN116209753A - 肺炎克雷伯氏菌o-抗原疫苗 - Google Patents

肺炎克雷伯氏菌o-抗原疫苗 Download PDF

Info

Publication number
CN116209753A
CN116209753A CN202180044800.1A CN202180044800A CN116209753A CN 116209753 A CN116209753 A CN 116209753A CN 202180044800 A CN202180044800 A CN 202180044800A CN 116209753 A CN116209753 A CN 116209753A
Authority
CN
China
Prior art keywords
klebsiella pneumoniae
polysaccharide
optionally
nucleotide sequence
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044800.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·卡兰萨·桑德迈尔
R·福拉多尔
V·G·丰克
S·J·克姆勒
P·M·基拉斯
M·T·科瓦里克
G·M·利波夫斯基
G·J·波施
F·塞尔文蒂
D·N·赛雷纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxosmithkline Biology Co ltd
Original Assignee
Glaxosmithkline Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biology Co ltd filed Critical Glaxosmithkline Biology Co ltd
Publication of CN116209753A publication Critical patent/CN116209753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99019—Undecaprenyl-diphosphooligosaccharide—protein glycotransferase (2.4.99.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180044800.1A 2020-06-25 2021-06-17 肺炎克雷伯氏菌o-抗原疫苗 Pending CN116209753A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
US63/043,883 2020-06-25
EP20182138.6 2020-06-25
EP20182139.4 2020-06-25
EP20182138 2020-06-25
PCT/EP2021/066343 WO2021259743A2 (en) 2020-06-25 2021-06-17 Vaccine

Publications (1)

Publication Number Publication Date
CN116209753A true CN116209753A (zh) 2023-06-02

Family

ID=76375084

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180044800.1A Pending CN116209753A (zh) 2020-06-25 2021-06-17 肺炎克雷伯氏菌o-抗原疫苗
CN202180045684.5A Pending CN115996749A (zh) 2020-06-25 2021-06-17 经修饰的外毒素a蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180045684.5A Pending CN115996749A (zh) 2020-06-25 2021-06-17 经修饰的外毒素a蛋白

Country Status (8)

Country Link
US (2) US20230226175A1 (https=)
EP (2) EP4171624A1 (https=)
JP (2) JP2023531242A (https=)
CN (2) CN116209753A (https=)
BR (2) BR112022023234A2 (https=)
CA (2) CA3185642A1 (https=)
MX (2) MX2022015734A (https=)
WO (2) WO2021259743A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120192388A (zh) * 2025-03-04 2025-06-24 江西澄实生物科技有限公司 一种预防肺炎克雷伯氏菌感染的疫苗及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240066109A1 (en) * 2020-12-31 2024-02-29 Vaxnewmo Llc Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
US20240263132A1 (en) * 2021-05-26 2024-08-08 Pfizer Inc. Recombinant expression of klebsiella pneumoniae o-antigens in escherichia coli
WO2023118033A1 (en) * 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
TW202432182A (zh) * 2022-10-24 2024-08-16 瑞士商愛杜西亞製藥有限公司 對抗克雷伯氏肺炎桿菌之疫苗
KR20250120353A (ko) * 2022-12-08 2025-08-08 이도르시아 파마슈티컬스 리미티드 클렙시엘라 뉴모니아에의 백신
WO2024146325A1 (zh) * 2023-01-06 2024-07-11 中国人民解放军军事科学院军事医学研究院 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用
GB202302579D0 (en) * 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032534A2 (en) * 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106062203A (zh) * 2013-10-11 2016-10-26 格林考瓦因有限公司 宿主细胞修饰的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2353814T3 (es) 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
JP2012533285A (ja) 2009-07-17 2012-12-27 オーシャン ハーベスト テクノロジー （カナダ） インコーポレイテッド 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物
NO2501406T3 (https=) 2009-11-19 2018-05-19
EP3281639B1 (en) 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3508579B1 (en) 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
WO2016020499A2 (en) 2014-08-08 2016-02-11 Glycovaxyn Ag Modified host cells for use in bioconjugate production
US9988426B2 (en) * 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492481A1 (en) * 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
JP2021528059A (ja) * 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
BR112022014555A2 (pt) * 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106062203A (zh) * 2013-10-11 2016-10-26 格林考瓦因有限公司 宿主细胞修饰的方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CLARKE BR等: "Molecular basis for the structural diversity in serogroup O2-antigen polysaccharides in Klebsiella pneumoniae", 《J BIOL CHEM》, vol. 293, no. 13, 12 February 2018 (2018-02-12), pages 4667 *
FOLLADOR R等: "The diversity of Klebsiella pneumoniae surface polysaccharides", 《MICROB GENOM》, vol. 2, no. 8, 25 August 2016 (2016-08-25), pages 000073 *
GREENFIELD LK等: "Synthesis of lipopolysaccharide O-antigens by ABC transporter-dependent pathways", 《CARBOHYDR RES》, vol. 365, 6 March 2012 (2012-03-06), pages 15 *
GUACHALLA LM等: "Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3", 《SCI REP》, vol. 7, no. 1, 26 July 2017 (2017-07-26), pages 6635 *
GUACHALLA LM等: "Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3", 《SCI REP》, vol. 7, no. 1, 26 June 2017 (2017-06-26), pages 5 *
HANSEN DS等: "Klebsiella pneumoniae lipopolysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries", 《J CLIN MICROBIOL》, vol. 37, no. 1, 31 January 1999 (1999-01-31), pages 59 *
KELLY SD等: "Klebsiella pneumoniae O1 and O2ac antigens provide prototypes for an unusual strategy for polysaccharide antigen diversification", 《J BIOL CHEM》, vol. 294, no. 28, 28 May 2019 (2019-05-28), pages 10863 *
SZIJÁRTÓ V等: "Both clades of the epidemic KPC-producing Klebsiella pneumoniae clone ST258 share a modified galactan O-antigen type", 《INT J MED MICROBIOL》, vol. 306, no. 2, 29 February 2016 (2016-02-29), pages 95 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120192388A (zh) * 2025-03-04 2025-06-24 江西澄实生物科技有限公司 一种预防肺炎克雷伯氏菌感染的疫苗及其应用

Also Published As

Publication number Publication date
BR112022024267A2 (pt) 2023-01-17
EP4171625A2 (en) 2023-05-03
MX2022016589A (es) 2023-02-01
MX2022015734A (es) 2023-01-18
US20230293657A1 (en) 2023-09-21
BR112022023234A2 (pt) 2023-01-03
JP2023531059A (ja) 2023-07-20
CN115996749A (zh) 2023-04-21
WO2021259743A3 (en) 2022-04-21
EP4171624A1 (en) 2023-05-03
JP7847091B2 (ja) 2026-04-16
JP2023531242A (ja) 2023-07-21
US20230226175A1 (en) 2023-07-20
CA3185639A1 (en) 2021-12-30
CA3185642A1 (en) 2021-12-30
WO2021259743A2 (en) 2021-12-30
WO2021259742A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
JP7847091B2 (ja) 肺炎桿菌ｏ抗原ワクチン
CN103079591B (zh) 荚膜革兰氏阳性细菌生物缀合物疫苗
KR101855142B1 (ko) 신규한 폴리사카라이드 및 이의 용도
KR20150054800A (ko) 변형된 항원을 포함하는 생체접합체 및 이의 용도
JP6998866B2 (ja) 緑膿菌ＰｃｒＶ連結型抗原ワクチン
AU2021342797B2 (en) Multivalent vaccine compositions and uses thereof
EP2741772A1 (en) Pasteurellaceae vaccines
CN106794237A (zh) 经修饰的宿主细胞及其用途
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
US20250381257A1 (en) Vaccine
WO2024175620A1 (en) Immunogenic composition
CN121693343A (zh) 经修饰的蛋白质
KR20260051063A (ko) 변형된 단백질
KR20260052081A (ko) 변형된 단백질
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
WO2025172892A1 (en) Modified proteins and methods
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination